#AS­CO18: Bris­tol-My­ers takes an­oth­er stab at a pos­i­tive im­pres­sion for Check­Mate-227

CHICA­GO — Af­ter get­ting snubbed at AACR in its show­down with Mer­ck over front­line lung can­cer, Bris­tol-My­ers Squibb is back at AS­CO with up­dat­ed da­ta on its check­point star Op­di­vo in com­bi­na­tion with chemo as well as a low dose of the CT­LA-4 drug Yer­voy. And it’s like­ly to still face an up­hill climb against the skep­tics.

That check­point plus chemo com­bo — where Mer­ck has been reign­ing supreme — came in with a haz­ard ra­tio of 0.74 among pa­tients with less than 1% PD-L1 ex­pres­sion. And the Op­di­vo/Yer­voy com­bo did bet­ter on pro­gres­sion-free sur­vival at this stage of the 1b por­tion of Check­Mate-227 when pa­tients are win­nowed down by the size of their tu­mor mu­ta­tion bur­den.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER